Source comparison
Peptides for Injury Recovery: Mechanisms Comparison
BPC-157 VEGF upregulation, angiogenesis promotion, fibroblast activation Tendons, ligaments, muscle, GI mucosa 250–500 mcg daily subcutaneous or oral Lyophilized: −20°C; Reconstituted: 2–8°C, use within 28 days Best-studied for soft tissue injuries. Strong pre
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, angiogenesis promotion, fibroblast activation
- Tendons, ligaments, muscle, GI mucosa
- 250–500 mcg daily subcutaneous or oral
- Lyophilized: −20°C; Reconstituted: 2–8°C, use within 28 days
- Best-studied for soft tissue injuries. Strong preclinical data, limited human trials
- TB-500 (Thymosin Beta-4)
- Actin polymerization, satellite cell migration, anti-inflammatory signaling
- Muscle tissue, tendons, cardiac tissue post-injury
- 2–5 mg twice weekly subcutaneous
- Effective for muscle strain and delayed-onset soreness. Commonly used in equine research
- PTH 1-34 (Teriparatide)
- Osteoblast stimulation, cAMP signaling, bone matrix synthesis
- Bone (fractures, stress fractures, osteoporotic bone)
- 20 mcg daily subcutaneous (FDA-approved therapeutic dose)
- Pre-filled pens: 2–8°C; Discard after 28 days
- FDA-approved for osteoporosis. Demonstrated fracture healing benefit in clinical studies
- GHK-Cu (Copper Peptide)
- Collagen synthesis, antioxidant activity, MMP modulation
- Skin, connective tissue, wound beds
- 1–3 mg topical or subcutaneous
- Lyophilized: −20°C; Reconstituted: 2–8°C, use within 21 days
- Primarily wound healing and dermal repair. Weaker evidence for deep tissue injuries